Acadia Pharma (ACAD) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 8, 2021 4:05 PM EST- 3Q21 net sales of $131.6 million, a 9% increase over 3Q20
- FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.
Our third-quarter results reflect volume growth across all channels and our strong relative performance underscores our commercial teams ability to drive sales of NUPLAZID in a challenging environment, said Steve Davis, Chief Executive Officer. As we... More
